Overall serious adverse events · people who smoke
1 finding from 1 review
Intervention not reported
Overall serious adverse events · people who smoke
1 finding from 1 review
Overall serious adverse events · people who smoke
Preloading nicotine replacement therapy (NRT) showed no clear difference in overall serious adverse events compared with standard‐use NRT (low certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Adverse events: kidney failure · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether steroids changes adverse events: kidney failure compared with no specific treatment (very low certainty).
1 finding from 1 review
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events or side effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Number of minor adverse events · Adults with overactive bladder (OAB)
Acupuncture showed no clear difference in number of minor adverse events compared with sham acupuncture (moderate certainty).
1 finding from 1 review
Major adverse events · Adults with overactive bladder (OAB)
1 finding from 1 review
Number of minor adverse events · Adults with overactive bladder (OAB)
Acupuncture may leads to lower number of minor adverse events compared with medication (low certainty).
1 finding from 1 review
Major adverse events · Adults with overactive bladder (OAB)
1 finding from 1 review
Number of minor adverse events · Adults with overactive bladder (OAB)
1 finding from 1 review